Your browser doesn't support javascript.
Use of ivermectin in the treatment of Covid-19: A pilot trial.
Pott-Junior, Henrique; Paoliello, Mônica Maria Bastos; Miguel, Alice de Queiroz Constantino; da Cunha, Anderson Ferreira; de Melo Freire, Caio Cesar; Neves, Fábio Fernandes; da Silva de Avó, Lucimar Retto; Roscani, Meliza Goi; Dos Santos, Sigrid De Sousa; Chachá, Silvana Gama Florêncio.
  • Pott-Junior H; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • Paoliello MMB; Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461, Bronx, New York, United States.
  • Miguel AQC; University Hospital of the Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • da Cunha AF; Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.
  • de Melo Freire CC; Department of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.
  • Neves FF; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • da Silva de Avó LR; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • Roscani MG; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • Dos Santos SS; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
  • Chachá SGF; Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Toxicol Rep ; 8: 505-510, 2021.
Article in English | MEDLINE | ID: covidwho-1135576
ABSTRACT

OBJECTIVES:

In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19.

METHODS:

Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466).

RESULTS:

A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests.

CONCLUSIONS:

Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Toxicol Rep Year: 2021 Document Type: Article Affiliation country: J.toxrep.2021.03.003

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Toxicol Rep Year: 2021 Document Type: Article Affiliation country: J.toxrep.2021.03.003